Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 24%
Hold 41%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. maintains a robust position in the biopharmaceutical sector, primarily driven by the sustained success of its lead product cabozantinib (Cabo), which has demonstrated strong long-term data supporting its efficacy in renal cell carcinoma (RCC) while expanding its label in neuroendocrine tumors (NETs). The company’s strategic collaborations, particularly with Natera for the STELLAR-316 trial, signal a proactive approach to advancing its pipeline, enhancing the potential for future growth. Furthermore, the favorable outcomes reported in the STELLAR-303 trial for zanzalintinib's combination therapy bolster Exelixis's prospects in the competitive landscape of metastatic colorectal cancer (mCRC).

Bears say

Exelixis Inc faces multiple risks that contribute to a negative outlook on its stock, particularly regarding its primary product, Cabometyx (cabozantinib), which may experience significant market share erosion due to competition and potential generic entry. Additionally, the company's ongoing clinical programs, especially those involving zanzalintinib, have demonstrated disappointing efficacy results that fell short of investor expectations, raising concerns about future revenue generation. Overall, the combination of commercial risks, long-term dilution possibilities, and regulatory uncertainties underscores a cautious perspective on Exelixis's financial health and stock valuation.

Exelixis (EXEL) has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 24% recommend Buy, 41% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 17 analysts, Exelixis (EXEL) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.